Cargando…
Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025258/ https://www.ncbi.nlm.nih.gov/pubmed/36935426 http://dx.doi.org/10.1038/s41392-023-01322-w |
| _version_ | 1784909288472313856 |
|---|---|
| author | Guan, Xiuwen Ma, Fei Li, Qiao Chen, Shanshan Fan, Ying Wang, Jiayu Luo, Yang Zhang, Pin Li, Qing Xu, Binghe |
| author_facet | Guan, Xiuwen Ma, Fei Li, Qiao Chen, Shanshan Fan, Ying Wang, Jiayu Luo, Yang Zhang, Pin Li, Qing Xu, Binghe |
| author_sort | Guan, Xiuwen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10025258 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100252582023-03-21 Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer Guan, Xiuwen Ma, Fei Li, Qiao Chen, Shanshan Fan, Ying Wang, Jiayu Luo, Yang Zhang, Pin Li, Qing Xu, Binghe Signal Transduct Target Ther Letter Nature Publishing Group UK 2023-03-19 /pmc/articles/PMC10025258/ /pubmed/36935426 http://dx.doi.org/10.1038/s41392-023-01322-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Guan, Xiuwen Ma, Fei Li, Qiao Chen, Shanshan Fan, Ying Wang, Jiayu Luo, Yang Zhang, Pin Li, Qing Xu, Binghe Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer |
| title | Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer |
| title_full | Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer |
| title_fullStr | Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer |
| title_full_unstemmed | Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer |
| title_short | Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer |
| title_sort | pyrotinib plus capecitabine could significantly improve overall survival in her2-positive metastatic breast cancer |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025258/ https://www.ncbi.nlm.nih.gov/pubmed/36935426 http://dx.doi.org/10.1038/s41392-023-01322-w |
| work_keys_str_mv | AT guanxiuwen pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT mafei pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT liqiao pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT chenshanshan pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT fanying pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT wangjiayu pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT luoyang pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT zhangpin pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT liqing pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer AT xubinghe pyrotinibpluscapecitabinecouldsignificantlyimproveoverallsurvivalinher2positivemetastaticbreastcancer |